Chemoinformaics analysis of 4,6,8(14)-Cholestatriene
| Molecular Weight | 366.633 | nRot | 5 |
| Heavy Atom Molecular Weight | 324.297 | nRig | 20 |
| Exact Molecular Weight | 366.329 | nRing | 4 |
| Solubility: LogS | -7.472 | nHRing | 0 |
| Solubility: LogP | 7.78 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 69 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 27 | No. of Aromatic Carbocycles | 0 |
| nHetero | 0 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 42 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 27 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 73.0953 |
| nHD | 0 | BPOL | 42.1347 |
| QED | 0.459 |
| Synth | 4.537 |
| Natural Product Likeliness | 2.669 |
| NR-PPAR-gamma | 0.507 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0.999 |
| Pgp-sub | 0.001 |
| HIA | 0.002 |
| CACO-2 | -5.043 |
| MDCK | 0.0000128 |
| BBB | 0.032 |
| PPB | 0.96583 |
| VDSS | 2.704 |
| FU | 0.0163866 |
| CYP1A2-inh | 0.099 |
| CYP1A2-sub | 0.553 |
| CYP2c19-inh | 0.286 |
| CYP2c19-sub | 0.957 |
| CYP2c9-inh | 0.209 |
| CYP2c9-sub | 0.543 |
| CYP2d6-inh | 0.578 |
| CYP2d6-sub | 0.434 |
| CYP3a4-inh | 0.742 |
| CYP3a4-sub | 0.824 |
| CL | 3.098 |
| T12 | 0.1 |
| hERG | 0.949 |
| Ames | 0.021 |
| ROA | 0.041 |
| SkinSen | 0.984 |
| Carcinogencity | 0.063 |
| EI | 0.689 |
| Respiratory | 0.937 |
| NR-Aromatase | 0.873 |
| Antiviral | No |
| Prediction | 0.751482 |